MetaVia reports Q3 net loss $3.4M, cash $14.3M; DA-1726 48mg cohort data due by year-end

MetaVia Inc.

2025-Q3 EPS reported -$0.63 vs consensus -$2.49 ▲ beat (+74.7%)

Net loss of $3.4M ($0.14 per share) vs $5.7M ($0.55) in Q3 2024; cash $14.3M expected to fund into 2026.
R&D expenses fell to $1.9M from $4.5M YoY; total operating expenses $3.5M.
Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data expected by year-end 2025.
Phase 1 DA-1726 data: 6.3% mean weight loss, 3.9-inch waist reduction, PK supports once-weekly dosing.
Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation, fibrosis; end-of-Phase 2 FDA meeting H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.